Quantinno Capital Management
TRDA icon

Quantinno Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Quantinno Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Buy
188,839
+117,821
+166% +$1.13M ﹤0.01% 2294
2026
Q1 		$896K Buy
71,018
+3,301
+5% +$37.8K ﹤0.01% 2255
2025
Q4 		$696K Buy
67,717
+9,488
+16% +$80K ﹤0.01% 2090
2025
Q3 		$338K Buy
58,229
+39,607
+213% +$232K ﹤0.01% 2359
2025
Q2 		$125K Buy
+18,622
New +$150K ﹤0.01% 2471

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5AM Venture Management
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Merck & Co
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MPM BioImpact
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
StepStone Group
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Quantinno Capital Management's TRDA Position: Q2 2026 in Review

Quantinno Capital Management increased its Entrada Therapeutics (TRDA) stake by 166% in Q2 2026, buying an estimated $1.13M and bringing the position to 188,839 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2294.

Quantinno Capital Management first reported a position in TRDA in Q2 2025 and has held it in 5 quarters since. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Quantinno Capital Management held 188,839 shares of Entrada Therapeutics worth $1.39M as of Q2 2026.
  • Quantinno Capital Management bought 117,821 Entrada Therapeutics shares in Q2 2026, an estimated $1.13M.
  • Entrada Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2294 holding.
  • Quantinno Capital Management first reported a position in Entrada Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.